Jubilant Biosys Ltd., a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd., recently announced the US FDA acceptance of the Investigational New Drug (IND) filing for a novel molecule targeting prostate cancer with Endo Pharmaceuticals in the US. This molecule will now progress towards the next phase of development and is anticipated to go into clinical trials by late 2013.

"We are very pleased and elated with this successful outcome, which is the result of excellent collaboration between the scientists at Endo and Jubilant Biosys. Being at the forefront in pharmaceuticals, life sciences and healthcare innovation, Jubilant pursues its goal to enable affordable healthcare to patients worldwide," said Dr SubirKumar Basak, president, Global Drug Discovery Services, Jubilant Life Sciences.

Added Dr Sandeep Gupta, senior vice president, Discovery & Early Development, Endo Pharmaceuticals, "I congratulate the Jubilant and Endo teams on achieving this important milestone. It was their outstanding collaborative work and ingenuity that enabled the successful filing and acceptance of an IND in less than three years. The IND filing and progression of the molecule to the next stage of development further validates Endo's unique collaborative drug discovery approach which aims to address unmet medical needs and improve patient outcomes."

The multi-target oncology collaboration between Jubilant and Endo began four years ago, and is focused on developing best-in-class, differentiated therapies that address the unmet needs of cancer patients worldwide. The collaboration has delivered on multiple milestones across the discovery continuum.

Jubilant Biosys Ltd. is a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd., which is headquartered in Noida, India. It provides integrated drug discovery solutions to the global pharmaceutical industry.